Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. - Wikidata - awgldk - TriplyDB

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

http://www.wikidata.org/entity/Q30426728

about

Bevacizumab for glioblastoma Twisted tango: brain tumor neurovascular interactions Medical management of brain tumors and the sequelae of treatment.A randomized trial of bevacizumab for newly diagnosed glioblastoma Angiogenic inhibition in high-grade gliomas: past, present and future.Antiangiogenic therapy of brain tumors: the role of bevacizumab.Chemotherapy-related changes in cognitive functioning.Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma.Verbal Learning Processes in Patients with Glioma of the Left and Right Temporal Lobes.Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain.Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD)Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations Neurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe Glioma Bevacizumab for the treatment of glioblastoma.Neurocognitive functioning in patients with glioma of the left and right temporal lobes Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors.Chemotherapy-related cognitive dysfunction.Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.Current status of antiangiogenic therapies for glioblastomas.Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma.Relationship between cognitive function and prognosis in glioblastoma.Antiangiogenic therapies for glioblastoma.Bevacizumab in recurrent glioblastoma: five informative patient scenarios.Neurocognitive functions and health-related quality of life in glioblastoma patients: a concise review of the literature.Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors.Illness intrusiveness and subjective well-being in patients with glioblastoma.Perspectives of Medical Specialists on Sharing Decisions in Cancer Care: A Qualitative Study Concerning Chemotherapy Decisions With Patients With Recurrent Glioblastoma.A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.Neurocognitive function: an emerging surrogate endpoint for neuro-oncology trials.Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma.Bevacizumab in Recurrent High-Grade Gliomas: A Canadian Retrospective Study.How treatment monitoring is influencing treatment decisions in glioblastomas.Refining endpoints in brain tumor clinical trials.

P2860

Q26776307-36B22275-4345-4FA5-847B-B872F61085A8 Q26849613-9F1796DE-27C2-4F71-8AB1-9B9204CCC203 Q26992174-8679DC65-AF5F-4A2D-90E1-7DEB685E4EB9 Q30410163-69A7C2B5-7172-4F98-A92A-454E69D7791B Q30455596-39B00578-B598-4372-A487-7C2911DE30DB Q30737224-D56D41DA-BF88-480E-86F4-4D9779B55A10 Q33697950-4877C92D-02C4-4BA2-9283-C498F110A9EC Q34234748-02F4273E-6C06-4976-97FD-6B9D8747AE6B Q36477893-413F423A-41D6-4578-AC92-E8578C144993 Q36589758-00777FF5-E951-48C0-9514-8EA5F591BFD7 Q36625206-0294411A-2EEA-4166-B4DB-9182A1186A8F Q36698172-65C35646-0C5C-4DF2-A254-E2A127BCFE23 Q36698177-1711BCF4-F401-4082-A159-FABF06638028 Q36797235-C1F0CA76-5E09-4F00-A1E3-4F72AF050C48 Q36929502-18D1D36E-5586-4B12-AA0A-872AC8B75FD7 Q36944818-194FB7A9-59A5-47CD-979A-5A703879359E Q37278376-042E0D7D-3B95-4F7C-90E9-2DC4D712A7A9 Q37278379-42C58701-C129-4B55-9B3F-BEF0ADBE42DD Q37350784-52CE64BD-9996-4968-9ABB-3052CA32E7E0 Q37986511-4E91AAEE-FDE1-4472-9829-0982D92948C3 Q37997653-9D932F50-FC18-4E8D-A978-6BEAAC3B20F3 Q38055317-626A335C-9272-4027-8FB8-7B16006D3479 Q38068203-F273B9B5-E2D7-4779-A0F0-BEF0EE8784B9 Q38169761-043AD9AA-AC28-4BB8-AD64-DA01BD23291B Q38178105-E7C1542B-31F1-42C8-8BE1-C7FF87A180F5 Q38233450-643A5C6D-FEAD-40A7-9E3A-F6E0DD23ADDD Q38264310-D9FC688A-8EB1-4B68-98C7-D1DC01A45F29 Q38409696-E120239F-42B7-499E-AA53-8F8E41E65609 Q38623875-DA3B3877-9DC7-4B9B-A562-1324AD55DE32 Q38779273-C6C787E0-D660-4CC6-99E8-11139B08EC19 Q39611554-915C4F31-9712-4B83-B6E5-8DE49BAB595C Q40485578-7FFECF78-4C51-447C-8A1C-1840EA5C9759 Q41450286-7D5CCEAA-975F-42F6-B3DD-EE2429E3AACF Q42113451-449CA01B-BAA0-40A1-943E-8C11E9F7F3A3 Q42745005-1012A171-D6E4-401E-B909-984BB1E0070D Q46605340-6A5D83FF-BCD8-4303-BF81-F498A84DDA35 Q47436703-3D956DDF-CB7A-4EBE-8493-395E14995E72 Q47450073-833B428C-8E66-44FF-B813-F36EF61C9A78 Q48292017-FE2C081C-AB5C-4CEE-8213-2A34DD984507 Q48462987-C06BD55E-4778-4B7A-8678-E6B1090BA01A

P2860

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

http://www.wikidata.org/entity/Q30426728

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

@ast

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

@en

type

label

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

@ast

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

@en

prefLabel

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

@ast

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

@en

P1433

Q30426728-5E703A09-CC17-4F3A-BCED-0C8170D7A9CD

P1476

Q30426728-61400E33-B58E-463C-BD42-16AE0A9FFE26

P2093

Q30426728-22F0F042-0805-4146-8421-8F4A28551C15

Q30426728-2A8307DE-39F5-42FA-95AD-43B17EBC9AC4

Q30426728-4217B182-A162-4FC7-A908-A08AD245B1D7

Q30426728-650127FE-8325-43DF-83AE-300C440A7AA4

Q30426728-6BFB2BE9-FBD8-46D6-B961-BD57392392C2

Q30426728-6E628848-839A-464D-B957-07E1EBD82A53

Q30426728-71B2483C-A86D-4B0D-9F5D-95E5E8D5BA07

Q30426728-7F26B9E0-6C0A-40C7-A405-E6E777005322

Q30426728-9913B235-2FFE-4465-8568-E75F56B83BE2

Q30426728-A6AA16CC-85BB-4B65-AF9B-C8B7638E09AF

P2860

Q30426728-0C6EE212-440D-4321-BB7D-5D9C98218E22

Q30426728-169DFB5B-CA18-4855-85C4-2A04445C1EDC

Q30426728-1866D865-EBF2-4E41-A40A-D56349962BFE

Q30426728-27F6F17B-178E-4362-BAE5-7930C52FDD9C

Q30426728-32D72DDE-0D29-44E5-86DA-C0F07D231765

Q30426728-4D9D7839-A08A-4E5B-A0F1-D296AE2DB5B9

Q30426728-5911BDC6-B2ED-434B-8AEF-3FD9ED2F5BDB

Q30426728-5CC9899B-E50F-49B3-B753-575B3A96E955

Q30426728-6240C3F9-B14C-448D-86B0-03729B68A472

Q30426728-7066B9A7-BAEC-4604-9074-FFAC79DEAC99

P304

Q30426728-CAA0EA73-2238-444C-AF48-8EE7C4F0D557

P31

Q30426728-263B1382-EA6C-4BD6-ADC9-DBDB5B2F7689

P356

Q30426728-446580CB-B47E-458C-93E5-6832FDBF1C67

P433

Q30426728-77A4508E-2025-4BBA-AE61-4B21D4760FAE

P478

Q30426728-0E62068E-9DDA-4574-969E-50B57DDD27D9

P50

Q30426728-116F470A-D55F-421D-B9E1-C8495C1D72CB

P577

Q30426728-6C96FACD-4F12-4C93-B792-8B358898F4FE

P5875

Q30426728-D834DE80-1AD3-444C-8203-E7E0050875CB

P698

Q30426728-15BAE821-3287-4987-B914-28E8A7D338BB

P921

Q30426728-A80480AF-FDAD-43BC-A89C-3D2F247FB140

P932

Q30426728-2DE6A600-1F79-454E-8DD8-76955947EB8D

P356

P1433

P1476

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

@en

P2093

Asha Das

http://www.w3.org/2001/XMLSchema#string

David Schiff

http://www.w3.org/2001/XMLSchema#string

James L Zazzali

http://www.w3.org/2001/XMLSchema#string

James Vredenburgh

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Wefel

http://www.w3.org/2001/XMLSchema#string

Lauren E Abrey

http://www.w3.org/2001/XMLSchema#string

Maoxia Zheng

http://www.w3.org/2001/XMLSchema#string

Martin K Nicholas

http://www.w3.org/2001/XMLSchema#string

Michael Prados

http://www.w3.org/2001/XMLSchema#string

Nina Paleologos

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Normative data for determining significance of test-retest differences on eight common neuropsychological instruments.

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.

Longitudinal changes in memory and executive functioning are associated with longitudinal change in instrumental activities of daily living in older adults

Facets and determinants of quality of life in patients with recurrent high grade glioma.

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

The course of neurocognitive functioning in high-grade glioma patients.

Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression.

Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors.

P304

660-668

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOR024

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Henry Seth Friedman

P577

2011-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51113177

http://www.w3.org/2001/XMLSchema#string

P698

21558074

http://www.w3.org/2001/XMLSchema#string

P921

P932

3107095

http://www.w3.org/2001/XMLSchema#string